Published in Breast Cancer Res Treat on June 05, 2014
A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer. Breast Cancer (Auckl) (2016) 0.79
A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat (2016) 0.76
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother (2008) 6.55
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol (2010) 4.62
Need to OPPOSE PROPOSED ACGME Common Program Requirements. J Am Osteopath Assoc (2012) 2.40
HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw (2006) 2.15
Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer (2005) 2.12
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood (2011) 2.03
Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. J Am Coll Cardiol (2005) 1.96
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol (2004) 1.82
Fighting fire with fire: rekindling the bevacizumab debate. N Engl J Med (2012) 1.69
Focused microwave phased array thermotherapy for primary breast cancer. Ann Surg Oncol (2002) 1.63
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol (2012) 1.57
Vulvar Langerhans cell histiocytosis: a case report and review of the literature. Gynecol Oncol (2003) 1.43
Survival effects of adjuvant chemoradiotherapy after resection for pancreatic carcinoma. Arch Surg (2010) 1.39
Prevention and Screening in Hereditary Breast and Ovarian Cancer. Oncology (Williston Park) (2016) 1.39
A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol (2013) 1.30
Treating breast cancer in the 21st century: emerging biological therapies. J Cancer (2013) 1.26
Molecular profiling for breast cancer: a comprehensive review. Biomark Cancer (2013) 1.23
Efficacy of trastuzumab. Cancer Res (2005) 1.22
Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status. Cancer Causes Control (2009) 1.08
Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J Transl Med (2013) 1.05
Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist (2002) 1.05
Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. Cancer (2012) 1.05
Upper gastrointestinal tumors: current status and future perspectives. Expert Rev Anticancer Ther (2008) 1.01
Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience. Cancer Invest (2002) 1.00
Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. Pharmacoeconomics (2014) 0.98
Stereotactic radiotherapy for treatment of cavernous sinus meningiomas. Int J Radiat Oncol Biol Phys (2004) 0.97
Adjuvant and preoperative therapy for localized gastric cancer. Gastrointest Cancer Res (2007) 0.97
Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model. Cancer Immunol Immunother (2007) 0.95
Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Res Treat (2011) 0.92
Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. J Clin Oncol (2014) 0.91
Successful treatment of anal gland adenocarcinoma with combined modality therapy. Gastrointest Cancer Res (2012) 0.90
Optimizing imatinib mesylate treatment in gastrointestinal stromal tumors. Gastrointest Cancer Res (2008) 0.88
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Semin Oncol (2004) 0.86
Interferon-gamma suppresses cyclooxygenase-2 promoter activity by inhibiting C-Jun and C/EBPbeta binding. Arterioscler Thromb Vasc Biol (2007) 0.86
Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. Cancer Treat Rev (2011) 0.86
Correlation between apoptotic endothelial microparticles and serum interleukin-6 and C-reactive protein in healthy men. Am J Cardiol (2005) 0.85
Gemcitabine and taxanes in metastatic breast cancer: a systematic review. Ther Clin Risk Manag (2008) 0.85
Trastuzumab plus chemotherapy: convincing survival benefit or not? J Clin Oncol (2005) 0.85
A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer. Breast Cancer Res Treat (2012) 0.84
Does race affect outcomes in triple negative breast cancer? Breast Cancer (Auckl) (2010) 0.84
High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review. Clin Ther (2009) 0.84
Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma. Cancer Biol Ther (2007) 0.84
Gastric small-cell carcinoma found on esophagogastroduodenoscopy: a case report and literature review. Case Rep Oncol Med (2013) 0.83
The glutathione disulfide mimetic NOV-002 inhibits cyclophosphamide-induced hematopoietic and immune suppression by reducing oxidative stress. Free Radic Biol Med (2012) 0.82
Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer. Cancer (2014) 0.82
Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer. Clin Breast Cancer (2007) 0.82
Oxaliplatin and fixed-rate infusional gemcitabine in the second-line treatment of patients with metastatic colon cancer: final results of a Phase II trial prematurely closed as a result of poor accrual. Clin Colorectal Cancer (2007) 0.81
The incidence of recurrent herpes simplex and herpes zoster infection during treatment with arsenic trioxide. J Drugs Dermatol (2006) 0.81
Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat (2014) 0.81
Weekly paclitaxel in women age 65 and above with metastatic breast cancer. Breast Cancer Res Treat (2002) 0.80
Clinical outcomes in breast cancer patients with HIV/AIDS: a retrospective study. Breast Cancer Res Treat (2015) 0.79
Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life. Clin Breast Cancer (2005) 0.79
Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancer. Cancer J (2003) 0.79
Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. BMC Cancer (2007) 0.78
Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review. J Med Case Rep (2012) 0.78
Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. BMC Cancer (2007) 0.78
Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma. Med Oncol (2011) 0.78
Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience. Breast Cancer Res Treat (2004) 0.77
A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer. Breast Cancer Res Treat (2013) 0.77
Pleomorphic lobular carcinoma of the breast: four long-term responders to trastuzumab--coincidence or hint? J Clin Oncol (2008) 0.76
The failed Theratope vaccine: 10 years later. J Am Osteopath Assoc (2012) 0.76
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. Invest New Drugs (2014) 0.76
A case of severe thrombotic thrombocytopenic purpura with concomitant Legionella pneumonia: review of pathogenesis and treatment. Am J Ther (2011) 0.76
Synergy of brief activation of CD8 T-cells in the presence of IL-12 and adoptive transfer into lymphopenic hosts promotes tumor clearance and anti-tumor memory. Am J Cancer Res (2011) 0.76
Docetaxel and carboplatin as first-line therapy in advanced non-small cell lung carcinoma: a phase II study. Anticancer Res (2004) 0.76
Patient with synchronous low grade leiomyosarcoma of the thigh, primary pancreatic neuroendocrine tumor, and lung metastases: Why biopsy of metastases should be the standard. J Gastrointest Oncol (2011) 0.75
Leveraging combinatorial chemotherapy to improve outcomes in patients with pancreatic cancer. Cancer Biol Ther (2010) 0.75
Understanding the biology of ex vivo-expanded CD8 T cells for adoptive cell therapy: role of CD62L. Immunol Res (2013) 0.75
Adjuvant external-beam radiotherapy in patients with high-risk well-differentiated thyroid cancer. Ear Nose Throat J (2009) 0.75
Strategies for individualizing management of patients with metastatic melanoma: a managed care perspective. Am J Manag Care (2015) 0.75
Kasabach-Merritt phenomenon in an adult man with a tufted angioma and cirrhosis responding to radiation, bevacizumab, and prednisone. Int J Dermatol (2014) 0.75
Support legislation to address shortage of chemotherapy drugs. J Am Osteopath Assoc (2012) 0.75
Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review. Cancer Biol Ther (2008) 0.75
Acute myeloid leukemia, genetics, and risk stratification: data overload or ready for a breakthrough? J Am Osteopath Assoc (2012) 0.75
Holding rhetoric to a new standard: what's the P value of that statement, senator? J Am Osteopath Assoc (2012) 0.75
Evaluating the Utility of a 'N-of-1' Precision Cancer Medicine Strategy: The Case for 'Time-to-Subsequent-Disease Progression'. Oncology (2016) 0.75